Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 11;229(1):19–29. doi: 10.1093/infdis/jiad220

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 4. — nAbs against RSV clinical isolates. GMFIs are shown from baseline to day 29 in nAbs against RSV A and B clinical isolates for participants receiving the HD/HD combination regimen (n = 24). For each isolate, A and B denote the RSV subtype, and the 2-digit number afterward denotes the year from which each strain was isolated. Ad26, adenovector 26; GMFI, geometric mean fold increase; HD, high dose; nAb, neutralizing antibody; preF, prefusion conformation-stabilized RSV F protein; RSV, respiratory syncytial virus. ^aA combination injection of Ad26.RSV.preF and recombinant RSV preF protein at the specified dosages. ^bInjections given in opposite arms.